|
|
肌层浸润性膀胱癌免疫治疗进展
|
Abstract:
肌层浸润性膀胱癌作为泌尿系统侵袭性最强的恶性肿瘤之一，传统的根治性膀胱切除术存在着创伤大、并发症多、患者生活质量下降等不足。近年来，以各类免疫检查点抑制剂，如程序性死亡受体1/程序性死亡受体配体1抑制剂为核心的围手术期免疫治疗策略显著改善了患者预后，治疗前景迎来了前所未有的拓展，免疫治疗逐渐展示出令人振奋的效果。有关基层浸润性膀胱癌的临床研究显示，免疫治疗不仅在晚期膀胱癌中是一种更安全、潜在有效的治疗选择，而且在疾病早期的治疗中也表现出良好的疗效。本文就肌层浸润性膀胱癌相关免疫治疗方面的进展及替雷利珠等免疫抑制剂在肌层浸润性膀胱癌中的应用展开综述。
Muscle-invasive bladder cancer (MIBC) is one of the most aggressive malignancies in the urological system, is traditionally managed with radical cystectomy. However, this approach is associated with high morbidity, significant complications, and compromised quality of life. In recent years, perioperative immunotherapy strategies centered on immune checkpoint inhibitors (ICIs), particularly programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have markedly improved patient prognosis, and the therapeutic landscape has undergone unprecedented expansion. Emerging clinical trials demonstrate that immunotherapy not only serves as a safer and potentially effective option for advanced bladder cancer but also exhibits promising efficacy in early-stage disease. This article provides a comprehensive review of recent advances in immunotherapy for MIBC, with a focus on the clinical applications of immune checkpoint inhibitors, particularly PD-1 inhibitors such as tislelizumab, in the management of this disease.
| [1] | 李辉章, 郑荣寿, 杜灵彬, 等. 中国膀胱癌流行现状与趋势分析[J]. 中华肿瘤杂志, 2021, 43(3): 293-298. |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [3] | Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J.A., et al. (2024) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. European Urology, 85, 17-31. https://doi.org/10.1016/j.eururo.2023.08.016 |
| [4] | Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763 |
| [5] | Ramani, V.A.C., Maddineni, S.B., Grey, B.R. and Clarke, N.W. (2010) Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis. European Urology, 57, 1058-1063. https://doi.org/10.1016/j.eururo.2009.12.002 |
| [6] | Gray, P.J., Fedewa, S.A., Shipley, W.U., Efstathiou, J.A., Lin, C.C., Zietman, A.L., et al. (2013) Use of Potentially Curative Therapies for Muscle-Invasive Bladder Cancer in the United States: Results from the National Cancer Data Base. European Urology, 63, 823-829. https://doi.org/10.1016/j.eururo.2012.11.015 |
| [7] | Powles, T., Rosenberg, J.E., Sonpavde, G.P., et al. (2025) NIAGARA: A Phase 3 Trial of Durvalumab Plus Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer. The Lancet Oncology, 26, 345-357. |
| [8] | Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J.A., et al. (2024) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. European Urology, 85, 17-31. https://doi.org/10.1016/j.eururo.2023.08.016 |
| [9] | Crispen, P.L. and Kusmartsev, S. (2019) Mechanisms of Immune Evasion in Bladder Cancer. Cancer Immunology, Immunotherapy, 69, 3-14. https://doi.org/10.1007/s00262-019-02443-4 |
| [10] | Serritella, A.V. and Shenoy, N.K. (2023) Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other than Melanoma: A Meta-Analysis. JAMA Oncology, 9, 1441-1446. https://doi.org/10.1001/jamaoncol.2023.3295 |
| [11] | Nishimura, H. and Honjo, T. (2001) PD-1: An Inhibitory Immunoreceptor Involved in Peripheral Tolerance. Trends in Immunology, 22, 265-268. https://doi.org/10.1016/s1471-4906(01)01888-9 |
| [12] | Sharma, P., Hu-Lieskovan, S., Wargo, J.A. and Ribas, A. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017 |
| [13] | Liu, Y. and Zheng, P. (2020) Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. Trends in Pharmacological Sciences, 41, 4-12. https://doi.org/10.1016/j.tips.2019.11.003 |
| [14] | Hu, J., Chen, J., Ou, Z., et al. (2022) Neoadjuvant Immunotherapy, Chemotherapy, and Combination Therapy in Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Retrospective Study. Cell Reports Medicine, 3, Article ID: 100785. https://doi.org/10.1016/j.xcrm.2022.100785 |
| [15] | Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Schenker, M., Valderrama, B.P., Tomita, Y., et al. (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine, 384, 2102-2114. https://doi.org/10.1056/nejmoa2034442 |
| [16] | Powles, T., Catto, J.W.F., Galsky, M.D., et al. (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. New England Journal of Medicine, 391, 1773-1786. https://doi.org/10.1056/NEJMoa2408154 |
| [17] | Zhou, L., Yang, K.W., Zhang, S., Yan, X.Q., Li, S.M., Xu, H.Y., et al. (2025) Disitamab Vedotin Plus Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (RC48-C014): A Phase IB/II Dose-Escalation and Dose-Expansion Study. Annals of Oncology, 36, 331-339. https://doi.org/10.1016/j.annonc.2024.12.002 |
| [18] | Wen, F., Lin, T., Zhang, P. and Shen, Y. (2024) RC48-ADC Combined with Tislelizumab as Neoadjuvant Treatment in Patients with HER2-Positive Locally Advanced Muscle-Invasive Urothelial Bladder Cancer: A Multi-Center Phase IB/II Study (Hope-03). Frontiers in Oncology, 13, Article 1233196. https://doi.org/10.3389/fonc.2023.1233196 |
| [19] | Balar, A.V., Kamat, A.M., Kulkarni, G.S., Uchio, E.M., Boormans, J.L., Roumiguié, M., et al. (2021) Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study. The Lancet Oncology, 22, 919-930. https://doi.org/10.1016/s1470-2045(21)00147-9 |
| [20] | Jackson-Spence, F., Toms, C., O’Mahony, L.F., Choy, J., Flanders, L., Szabados, B., et al. (2023) IMvigor011: A Study of Adjuvant Atezolizumab in Patients with High-Risk MIBC Who Are CTDNA+ Post-Surgery. Future Oncology, 19, 509-515. https://doi.org/10.2217/fon-2022-0868 |
| [21] | Necchi, A., Raggi, D., Gallina, A., et al. (2020) Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in MIBC (PURE-01). Journal of Clinical Oncology, 38, 3353-3362. |
| [22] | Netto, G.J. (2016) Role for Anti-PD-L1 Immune Checkpoint Inhibitor in Advanced Urothelial Carcinoma. The Lancet, 387, 1881-1882. https://doi.org/10.1016/s0140-6736(16)00654-1 |
| [23] | Galsky, M.D., Sfakianos, J.P., Ye, D., He, D., Hu, H., Song, X., et al. (2024) Oral APL-1202 in Combination with Tislelizumab as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC): Interim Analysis of Anticipate Phase II Trial. Journal of Clinical Oncology, 42, 632-632. https://doi.org/10.1200/jco.2024.42.4_suppl.632 |
| [24] | Li, K., Zhong, W., Fan, J., Wang, S., Yu, D., Xu, T., et al. (2024) Neoadjuvant Gemcitabine-Cisplatin Plus Tislelizumab in Persons with Resectable Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase 2 Trial. Nature Cancer, 5, 1465-1478. https://doi.org/10.1038/s43018-024-00822-0 |
| [25] | Zhao, Z., Liu, S., Zhou, T., Chen, G., Long, H., Su, X., et al. (2024) Stereotactic Body Radiotherapy with Sequential Tislelizumab and Chemotherapy as Neoadjuvant Therapy in Patients with Resectable Non-Small-Cell Lung Cancer in China (SACTION01): A Single-Arm, Single-Centre, Phase 2 Trial. The Lancet Respiratory Medicine, 12, 988-996. https://doi.org/10.1016/s2213-2600(24)00215-7 |
| [26] | Bellmunt, J., Hussain, M., Gschwend, J.E., Albers, P., Oudard, S., Castellano, D., et al. (2021) Adjuvant Atezolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (IMvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 525-537. https://doi.org/10.1016/s1470-2045(21)00004-8 |
| [27] | Janikovits, J., Müller, M., Krzykalla, J., Körner, S., Echterdiek, F., Lahrmann, B., et al. (2017) High Numbers of PDCD1 (Pd-1)-Positive T Cells and B2M Mutations in Microsatellite-Unstable Colorectal Cancer. OncoImmunology, 7, e1390640. https://doi.org/10.1080/2162402x.2017.1390640 |
| [28] | Sun, J., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X., et al. (2020) Resistance to PD-1/PD-L1 Blockade Cancer Immunotherapy: Mechanisms, Predictive Factors, and Future Perspectives. Biomarker Research, 8, Article No. 35. https://doi.org/10.1186/s40364-020-00212-5 |
| [29] | Williams, S., Cutie, C., Keegan, K.A., Raybold, B., Stewart, R., Acharya, M., et al. (2021) Sunrise-2: A Phase 3, Multicenter, Randomized Study Evaluating the Efficacy of TAR-200 in Combination with Cetrelimab versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology Open Science, 33, S376. https://doi.org/10.1016/s2666-1683(21)03201-8 |
| [30] | Liu, J., Wang, H., Li, X., et al. (2024) Safety and Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy for MIBC: A Retrospective Analysis. ModMed Urology, 29, 1-10. |
| [31] | Witjes, J.A., Bruins, H.M., Cathomas, R., Compérat, E.M., Cowan, N.C., Gakis, G., et al. (2021) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79, 82-104. https://doi.org/10.1016/j.eururo.2020.03.055 |
| [32] | Raggi, D. and Huddart, R.A. (2024) Transformative or Transitional? Deciphering the Role of NIAGARA in Shaping Future Practice. Med, 5, 1456-1458. https://doi.org/10.1016/j.medj.2024.11.004 |
| [33] | European Association of Urology (EAU) (2023) Guidelines on Muscle-Invasive and Metastatic Bladder Cancer (2023 Edition). European Urology, 84, 789-801. |
| [34] | Loriot, Y., Necchi, A., Park, S.H., Garcia-Donas, J., Huddart, R., Burgess, E., et al. (2019) Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 381, 338-348. https://doi.org/10.1056/nejmoa1817323 |
| [35] | Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., et al. (2014) Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens. Nature, 515, 577-581. https://doi.org/10.1038/nature13988 |
| [36] | Li, R., Shah, P.H., Stewart, T.F., Nam, J.K., Bivalacqua, T.J., Lamm, D.L., et al. (2024) Author Correction: Oncolytic Adenoviral Therapy Plus Pembrolizumab in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: The Phase 2 CORE-001 Trial. Nature Medicine, 30, 2372-2372. https://doi.org/10.1038/s41591-024-03137-w |
| [37] | Cuellar, M.A., Medina, A., Girones, R., Valderrama, B.P., Font, A., Juan-fita, M., et al. (2020) Phase II Trial of Durvalumab Plus Tremelimumab with Concurrent Radiotherapy as Bladder-Sparing Therapy in Patients with Localized Muscle Invasive Bladder Cancer: A SOGUG Study. Journal of Clinical Oncology, 38, TPS5097. https://doi.org/10.1200/jco.2020.38.15_suppl.tps5097 |
| [38] | Rose, T.L., Milowsky, M.I., Fraietta, J.A., et al. (2021) Phase 2 Study of Enfortumab Vedotin in Metastatic Urothelial Cancer. Journal of Clinical Oncology, 39, 4517. |
| [39] | Chinese Society of Clinical Oncology (CSCO) (2024) Expert Consensus on Multidisciplinary Management of Bladder Preservation for MIBC (2024 Edition). Chinese Journal of Oncology, 46, 891-905. |
